Vol 3, No 1 (2012)
Review paper
Published online: 2012-04-24

open access

Page views 613
Article views/downloads 2279
Get Citation

Connect on Social Media

Connect on Social Media

The role of the high-dose chemotherapy supported by autologous hematopoietic stem cell transplantation in the therapeutic plan of patients with acute myeloid leukemia

Sebastian Grosicki
Hematologia 2012;3(1):25-32.

Abstract

The age of patients with acute myeloid leukemia (AML) determines the therapeutic plan forthese patients. The aim of the therapy in younger ones is cure. In the face of very high degree ofheterogeneity of leukemic myeloblasts with regard to immunophenotype and mechanisms ofleukemogenesis, the search for effective targeted treatment is still ineffective. Allogeneichematopoietic stem cells transplantation gives a chance of cure in the unfavorable and intermediatesubgroup of AML. However, due to limited accesses to HLA-matched hematopoietic stem cell donors, in the intermediate and favorable risk subgroups of AML, and especially inpatients below 60 years with negative minimal residual disease, autologous hematopoieticstem cells transplantation is a valuable option.

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice